Kai Cheng
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Protease and Inhibitor Mechanisms
- Oncology top 10%
- Peptidase Inhibition and Analysis
Papers in
-
- Bioactive natural compounds 4
- Kruppel-like factors research 2
- Oncology 15
- Peptidase Inhibition and Analysis 8
- Cancer Cells and Metastasis 3
- Co-authors
- Zhenlin Yang (9 shared papers)Yong Han (6 shared papers)Luna Ge (9 shared papers)Jianli Dong (3 shared papers)Guoqiang Zhang (3 shared papers)Yuchun Wei (5 shared papers)Xiaohong Wang (4 shared papers)Jinming Yu (2 shared papers)
- Journals
- European Journal of Nuclear Medicine and Molecular Imaging (5 papers)Theranostics (3 papers)Pharmacology Research & Perspectives (2 papers)Frontiers in Oncology (2 papers)Scientific Reports (2 papers)
- Partner nations
- ChinaUnited KingdomHong Kong
In The Last Decade
Kai Cheng
50 papers receiving 856 citations
Peers
Comparison fields: 5 of 89
- Cancer Research 201
- Oncology 213
- Toxicology 22
- Molecular Biology 353
- Plant Science 137
Countries citing papers authored by Kai Cheng
This map shows the geographic impact of Kai Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Cheng more than expected).
Fields of papers citing papers by Kai Cheng
This network shows the impact of papers produced by Kai Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Cheng. The network helps show where Kai Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Kai Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 65 | |
| 2 | 2020 | 58 | |
| 3 | 2022 | 55 | |
| 4 | 2016 | 51 | |
| 5 | 2021 | 43 | |
| 6 | 2020 | 43 | |
| 7 | 2016 | 39 | |
| 8 | 2016 | 37 | |
| 9 | 2018 | 35 | |
| 10 | 2022 | 34 | |
| 11 | 2018 | 30 | |
| 12 | 2017 | 26 | |
| 13 | 2015 | 24 | |
| 14 | 2020 | 22 | |
| 15 | 2019 | 22 | |
| 16 | 2023 | 21 | |
| 17 | 2019 | 20 | |
| 18 | Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer. | 2020 | 19 |
| 19 | 2015 | 16 | |
| 20 | 2007 | 15 |
About Kai Cheng
Kai Cheng is a scholar working on Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Pulmonary and Respiratory Medicine, having authored 53 papers that have together received 865 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Protease and Inhibitor Mechanisms (4 papers), Bioactive natural compounds (4 papers), Cancer Cells and Metastasis (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Kruppel-like factors research (2 papers) and Bioactive Compounds and Antitumor Agents (2 papers). The work is most often cited by research in Cancer Research (201 citations), Oncology (213 citations), Toxicology (22 citations), Molecular Biology (353 citations) and Plant Science (137 citations). Kai Cheng has collaborated with scholars based in China, United Kingdom and Hong Kong. Frequent co-authors include Zhenlin Yang, Yong Han, Luna Ge, Jianli Dong, Guoqiang Zhang, Yuchun Wei, Xiaohong Wang, Jinming Yu, Xiaohong Wang and Jinsong Zheng. Their work appears in journals such as European Journal of Nuclear Medicine and Molecular Imaging, Theranostics, Pharmacology Research & Perspectives, Frontiers in Oncology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.